Prevalence of visible disruption of cervical epithelium and cervical ectopy in african women using depo-provera®

Contraception

Volumn 59, Issue 6, 1999, Pages 363-367

  Kuhn, Louise ^a   Denny, Lynette ^b   Pollack, Amy E ^c   Wright, Thomas C ^d  

^a Taub Institute for Research on Alzheimer's Disease and the Aging Brain and the Gertrude H Sergievsky Center   (United States)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c AVSC International   (United States)

^d NONE   (United States)

Author keywords

Africa; Cervical ectopy; Cervical inflammation; Heterosexual HIV transmission; Hormonal contraception; Progesterone

Indexed keywords

MEDROXYPROGESTERONE ACETATE; PROGESTERONE;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; HORMONAL CONTRACEPTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; INFLAMMATION; MAJOR CLINICAL STUDY; UTERINE CERVIX; UTERINE CERVIX EPITHELIUM; VIRUS INFECTION;

AFRICA; BIOLOGY; CERVICAL EFFECTS; CERVIX; CLINICAL RESEARCH; CONTRACEPTION; CONTRACEPTIVE AGENTS; CONTRACEPTIVE AGENTS, FEMALE; CONTRACEPTIVE AGENTS, PROGESTIN; CONTRACEPTIVE METHODS; DEPO-PROVERA; DEVELOPING COUNTRIES; FAMILY PLANNING; GENITALIA; GENITALIA, FEMALE; INJECTABLES; MEDROXYPROGESTERONE ACETATE; PHYSIOLOGY; RESEARCH METHODOLOGY; RESEARCH REPORT; UROGENITAL SYSTEM; UTERUS;

ADULT; AGED; AGING; ATROPHY; CERVIX UTERI; CONTRACEPTIVE AGENTS, FEMALE; EPITHELIUM; FEMALE; HUMANS; MEDROXYPROGESTERONE 17-ACETATE; MIDDLE AGED; ODDS RATIO; PARITY; SOUTH AFRICA; ULCER; UTERINE CERVICAL DISEASES; UTERINE CERVICITIS;

EID: 0032847417     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0010-7824(99)00049-9     Document Type: Article

References (13)

1. Marx P.A., Spira A.I., Gettie A., et al. Progesterone implants enhance SIV vaginal transmission and early virus load. Nature Med. 2:1996;1084-1089.
2. Daly C.C., Helling-Giese G.E., Mati J.K., Hunter D.J. Contraceptive methods and the transmission of HIV implications for family planning . Genitourin Med. 70:1994;110-117.
3. Stephenson J.M. Systematic review of hormonal contraception and risk of HIV transmission when to resist meta-analysis . AIDS. 12:1998;545-553.
4. Denny L, Kuhn L, Risi L, et al. Two-stage cervical cancer screening: an alternative for resource-poor settings; submitted.
5. Manual for the Standardization of Colposcopy for the Evaluation of Vaginally Administered Products. 1994;World Health Organization, Geneva.
6. Gilmour E., Ellerbrock T.V., Koulos J., et al. Measuring cervical ectopy direct visual assessment versus computerized planimetry . Am J Obstet Gynecol. 176:1997;108-111.
7. Runganga A., Pitts M., McMaster J. The use of herbal and other agents to enhance sexual experience. Soc Sci Med. 35:1992;1037-1042.
8. Dallabetta G.A., Miotti P.G., Chiphangwi J.D., Liomba G., Canner J.K., Saah A.J. Traditional vaginal agents use and association with HIV infection in Malawian women . AIDS. 9:1995;293-297.
9. Peterman T.A., Stoneburner R.L., Allen J.R., Jaffe H.W., Curran J.W. Risk of human immunodeficiency virus transmission from heterosexual adults with transfusion-associated infections. JAMA. 259:1988;55-58.
10. Plourde P.J., Pepin J., Agoki E., et al. Human immunodeficiency virus type 1 seroconversion in women with genital ulcers. J Infect Dis. 170:1994;313-317.
11. Alexander N.J. Sexual transmission of human immunodeficiency virus virus entry into the male and female genital tract . Fertil Steril. 54:1990;1-18.
12. Kreiss J., Willerford D.M., Hensel M., et al. Association between cervical inflammation and cervical shedding of human immunodeficiency virus DNA. J Infect Dis. 170:1994;1597-1601.
13. Elias C.J., Heise L.L. Challenges for the development of female-controlled vaginal microbicides. AIDS. 8:1994;1-9.